Applied Therapeutics Inc (NASDAQ: APLT) on Monday, plunged -3.92% from the previous trading day, before settling in for the closing price of $0.32. Within the past 52 weeks, APLT’s price has moved between $0.29 and $10.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 26.57% over the last five years. The company achieved an average annual earnings per share of 23.30%. With a float of $116.71 million, this company’s outstanding shares have now reached $141.58 million.
The firm has a total of 35 workers. Let’s measure their productivity. In terms of profitability, gross margin is 24.15%, operating margin of -41030.19%, and the pretax margin is -16419.25%.
Applied Therapeutics Inc (APLT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Applied Therapeutics Inc is 17.56%, while institutional ownership is 74.93%. The most recent insider transaction that took place on Mar 04 ’25, was worth 4,561. In this transaction Chief Medical Officer of this company sold 10,366 shares at a rate of $0.44, taking the stock ownership to the 890,409 shares. Before that another transaction happened on Mar 04 ’25, when Company’s insider sold 14,502 for $0.44, making the entire transaction worth $6,381. This insider now owns 390,459 shares in total.
Applied Therapeutics Inc (APLT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 23.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.33% during the next five years compared to 26.57% growth over the previous five years of trading.
Applied Therapeutics Inc (NASDAQ: APLT) Trading Performance Indicators
Applied Therapeutics Inc (APLT) is currently performing well based on its current performance indicators. A quick ratio of 3.00 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 163.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Applied Therapeutics Inc (APLT)
Analysing the last 5-days average volume posted by the [Applied Therapeutics Inc, APLT], we can find that recorded value of 4.62 million was better than the volume posted last year of 2.99 million. As of the previous 9 days, the stock’s Stochastic %D was 42.68%.
During the past 100 days, Applied Therapeutics Inc’s (APLT) raw stochastic average was set at 3.99%, which indicates a significant decrease from 10.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 119.68% in the past 14 days, which was higher than the 118.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3896, while its 200-day Moving Average is $2.7885. Now, the first resistance to watch is $0.3279. This is followed by the second major resistance level at $0.3446. The third major resistance level sits at $0.3531. If the price goes on to break the first support level at $0.3027, it is likely to go to the next support level at $0.2942. Now, if the price goes above the second support level, the third support stands at $0.2775.
Applied Therapeutics Inc (NASDAQ: APLT) Key Stats
Market capitalization of the company is 44.04 million based on 141,576K outstanding shares. Right now, sales total 460 K and income totals -105,620 K. The company made 0 K in profit during its latest quarter, and 44,010 K in sales during its previous quarter.
